Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2012, Article ID 250479, 6 pages
http://dx.doi.org/10.1155/2012/250479
Review Article

Is There a Role for Neoadjuvant Targeted Therapy to Downsize Primary Tumors for Organ Sparing Strategies in Renal Cell Carcinoma?

Division of Surgical Oncology, Department of Urology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Received 2 March 2012; Revised 26 April 2012; Accepted 7 May 2012

Academic Editor: Alessandro Volpe

Copyright © 2012 A. Bex et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Sun, F. Abdollah, M. Bianchi, Q. D. Trinh, C. Jeldres, R. Thuret et al., “Treatment management of small renal masses in the 21st century: a paradigm shift,” Annals of Surgical Oncology. In press.
  2. G. Yang, J. D. Villalta, M. V. Meng, and J. M. Whitson, “Evolving practice patterns forthe management of small renal masses in the USA,” BJU International . In press.
  3. J. Guillotreau, G.-P. Haber, R. Autorino et al., “Robotic partial nephrectomy versus laparoscopic cryoablation for the small renal mass,” European Urology, vol. 61, no. 5, pp. 899–904, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Kunkle and R. G. Uzzo, “Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis,” Cancer, vol. 113, no. 10, pp. 2671–2680, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. D. A. Kunkle, B. L. Egleston, and R. G. Uzzo, “Excise, ablate or observe: the small renal mass dilemma-a meta-analysis and review,” Journal of Urology, vol. 179, no. 4, pp. 1227–1234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. D. C. Miller, M. Schonlau, M. S. Litwin, J. Lai, and C. S. Saigal, “Renal and cardiovascular morbidity after partial or radical nephrectomy,” Cancer, vol. 112, no. 3, pp. 511–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Kates, G. M. Badalato, M. Pitman, and J. M. McKiernan, “Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less,” Journal of Urology, vol. 186, no. 4, pp. 1247–1253, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. J. Weight, G. Lieser, B. T. Larson et al., “Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours,” European Urology, vol. 58, no. 2, pp. 293–298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Touijer, D. Jacqmin, L. R. Kavoussi et al., “The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications,” European Urology, vol. 57, no. 2, pp. 214–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Van Poppel, L. Da Pozzo, W. Albrecht et al., “A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma,” European Urology, vol. 59, no. 4, pp. 543–552, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Ljungberg, N. C. Cowan, D. C. Hanbury et al., “EAU guidelines on renal cell carcinoma: the 2010 update,” European Urology, vol. 58, no. 3, pp. 398–406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. Okhunov, S. Rais-Bahrami, A. K. George et al., “The comparison of three renal tumor scoring systems: C-index, P.A.D.U.A., and R.E.N.A.L. nephrometry scores,” Journal of Endourology, vol. 25, no. 12, pp. 1921–1924, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Ficarra, G. Novara, S. Secco et al., “Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery,” European Urology, vol. 56, no. 5, pp. 786–793, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” Journal of Urology, vol. 182, no. 3, pp. 844–853, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. Zagoria, J. A. Pettus, M. Rogers, D. M. Werle, D. Childs, and J. R. Leyendecker, “Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma,” Urology, vol. 77, no. 6, pp. 1393–1397, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Ansari, A. Doherty, I. McCafferty, M. Wallace, N. Deshmukh, and E. Porfiri, “Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma,” Clinical Genitourinary Cancer, vol. 7, no. 2, pp. E39–E41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. R. J. Motzer and R. M. Bukowski, “Targeted therapy for metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 24, no. 35, pp. 5601–5608, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. T. E. Hutson, R. M. Bukowski, C. L. Cowey, R. Figlin, B. Escudier, and C. N. Sternberg, “Sequential use of targeted agents in the treatment of renal cell carcinoma,” Critical Reviews in Oncology/Hematology, vol. 77, no. 1, pp. 48–62, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. N. J. Vogelzang, W. Samlowski, and A. Weissman, “Long-term response in primary renal cancer to sequential antiangiogenic therapy,” Journal of Clinical Oncology, vol. 27, no. 26, pp. e106–e107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. E. J. Abel, S. H. Culp, N. M. Tannir et al., “Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma,” European Urology, vol. 59, no. 1, pp. 10–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Jonasch, C. G. Wood, S. F. Matin et al., “Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4076–4081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Powles, I. Kayani, C. Blank et al., “The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer,” Annals of Oncology, vol. 22, no. 5, pp. 1041–1047, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Yuasa, S. Urakami, S. Yamamoto et al., “Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer,” Urology, vol. 77, no. 4, pp. 831–835, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Bex, C. Blank, W. Meinhardt, H. van Tinteren, S. Horenblas, and J. Haanen, “A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ,” Urology, vol. 78, no. 4, pp. 832–837, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. C. L. Cowey, C. Amin, R. S. Pruthi et al., “Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma,” Journal of Clinical Oncology, vol. 28, no. 9, pp. 1502–1507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. N. J. Hellenthal, W. Underwood, R. Penetrante et al., “Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma,” Journal of Urology, vol. 184, no. 3, pp. 859–864, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. L. Silberstein, F. Millard, R. Mehrazin et al., “Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery,” BJU International, vol. 106, no. 9, pp. 1270–1276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. A. M. van der Veldt, M. R. Meijerink, A. J. M. van den Eertwegh et al., “Sunitinib for treatment of advanced renal cell cancer: primary tumor response,” Clinical Cancer Research, vol. 14, no. 8, pp. 2431–2436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Gorin, O. Ekwenna, M. S. Soloway, and G. Ciancio, “Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery,” Urology, vol. 79, no. 2, p. e11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Hudes, M. Carducci, P. Tomczak et al., “Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 22, pp. 2271–2281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Bex, E. Jonasch, Z. Kirkali et al., “Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials,” European Urology, vol. 58, no. 6, pp. 819–828, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Escudier, J. Roigas, S. Gillessen et al., “Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4068–4075, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. US National Institutes of Health, “Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer,” ClinicalTrials gov 2012, http://clinicaltrials.gov/ct2/show/NCT01158521.
  35. US National Institutes of Health, “Neoadjuvant pazopanib in renal cell carcinoma,” ClinicalTrials gov 2012, http://clinicaltrials.gov/ct2/show/NCT01361113.
  36. US National Institutes of Health, “Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC),” ClinicalTrials gov 2012, http://clinicaltrials.gov/ct2/show/NCT01263769.
  37. V. Margulis, S. F. Matin, N. Tannir et al., “Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma,” Journal of Urology, vol. 180, no. 1, pp. 94–98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. E. J. Abel, S. H. Culp, N. M. Tannir, P. Tamboli, S. F. Matin, and C. G. Wood, “Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib,” European Urology, vol. 60, no. 6, pp. 1273–1279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Bex, A. A. M. van der Veldt, C. Blank et al., “Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery,” World Journal of Urology, vol. 27, no. 4, pp. 533–539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Bex, A. A. M. van der Veldt, C. Blank, M. R. Meijerink, E. Boven, and J. B. A. G. Haanen, “Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib,” Acta Oncologica, vol. 49, no. 4, pp. 520–523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. J. M. L. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, and R. S. Kerbel, “Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis,” Cancer Cell, vol. 15, no. 3, pp. 232–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. J. Conley, E. Gheordunescu, P. Kakarala et al., “Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 8, pp. 2784–2789, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. V. G. Cooke, V. S. LeBleu, D. Keskin et al., “Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway,” Cancer Cell, vol. 21, no. 1, pp. 66–81, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Powles, C. Blank, S. Chowdhury et al., “The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer,” European Urology, vol. 60, no. 3, pp. 448–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. C. J. Long, D. J. Canter, A. Kutikov et al., “Partial nephrectomy for renal masses 7 cm: technical, oncological and functional outcomes,” BJU International, vol. 109, no. 10, pp. 1450–1456, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. C. R. Harris, J. M. Whitson, and M. V. Meng, “Under-grading of <4 cm renal masses on renal biopsy,” BJU International. In press.
  47. C. M. Tobert, R. G. Uzzo, C. G. Wood, and B. R. Lane, “Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology,” Urologic Oncology. In press.